Symptom control
Pain Pain control is achievable in 80% of patients by following the World Health Organisation's guidelines for use of analgesic drugs, as outlined in the first chapter of this series. A patient's history and examination are used to assess all likely causes of pain, both benign and malignant. Treatment (usually with an opioid) is individually tailored, the effect reviewed, and dose titrated accordingly. Acute episodes of pain are dealt with urgently in the same analytical fashion but require more frequent review and provision of appropriate "breakthrough" analgesia. If a patient is already receiving analgesia then this is continued through the final stages; pain may disturb an unconscious patient since the original cause of the pain still exists.
If oral administration is no longer possible the subcutaneous route provides a simple and effective alternative. Diamorphine is the strong opioid of choice because of its solubility and is delivered through a syringe driver device to avoid repeated injections every four hours. It can be mixed with other "essential" drugs in the syringe driver. Rectal administration is another alternative, but the need for suppositories every four hours in
Principles of managing the last 48 hours
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Routes of administration of drugs for last 48 hours Oral

All drug types
Sublingual Antiemetic
Sedative or anxiolytic
Hyoscine hydrobromide 0.3 mg/6 hours (Kwells) Prochlorperazine 3-6 mg/12 hours Lorazepam 0.5-2 mg/6 hours (fast acting and short duration) Diazepam (also anxiolytic and anticonvulsant) rectal tubes 5-10 mg *All subcutaneous preparations diluted in sterile water except diclofenac (0.9% saline) †Compatible with diamorphine but liable to precipitate as concentrations increase ‡Compatible with diamorphine the case of morphine limits its usefulness. Oxycodone suppositories (repeated 8 hourly) may be more practicable.
Longer acting opioid preparations (transdermal fentanyl and sustained release morphine) should not be started in a patient close to death; there is a variable delay in reaching effective levels, and, since speedy dose titration is difficult, they are unsuitable for situations where a rapid effect is required, such as uncontrolled pain. If a patient is already prescribed fentanyl patches these should be continued as baseline analgesia; if pain escalates additional quick acting analgesia (immediate release morphine or diamorphine) should be titrated against the pain.
Not all pains are best dealt with by opioids. For example, bone pain may be helped by a non-steroidal anti-inflammatory drug, while muscle spasm may be eased by diazepam. Non-drug measures still apply: for example, pain from a dry mouth requires mouth care; a pressure sore requires a change of position, a comfort dressing, local anaesthetic gel, and an appropriate mattress; and a distended bladder and loaded rectum require catheterisation and rectal evacuation respectively. It is also important to remember all the non-cancer pains, new and old, that may be present.
Breathlessness
The scope for correcting "reversible" causes of breathlessness becomes limited. A notable exception is cardiac failure, for which diuresis may be effective. In most cases the priority is to address the symptom of breathlessness and the fear and anxiety that may accompany it.
General supportive measures should be considered in all cases. Face masks may be uncomfortable or intrusive at this time, but oxygen therapy may help some patients (even in the absence of hypoxia). Nebulised 0.9% saline is useful if a patient has a dry cough or sticky secretions but should be avoided if bronchospasm is present.
Opioids and benzodiazepines can be helpful and should be initiated at low doses. Immediate release morphine can be titrated to effect in the same way as for pain. If a patient is using morphine for pain control then a dose slightly higher than the appropriate breakthrough dose (oral or parenteral) is usually required for treating acute breathlessness. The choice of anxiolytic is often determined by what is the most suitable route of administration, but the speed and duration of action are important.
Noisy respiration may be helped by repositioning the patient and, if substantial secretions are present, hyoscine hydrobromide (0.4-0.6 mg subcutaneous bolus or up to 2.4 mg/24 hours via syringe driver). Occasionally, gentle suction may be required. End stage stridor is managed with opioids and anxiolytics, when it is usually too late for corticosteroids.
Restlessness and confusion
These may be distinct entities or they may overlap. A problem solving approach is essential. The threshold for discomfort and disorientation is often lowered in cachectic or anxious patients. Attention to a patient's surroundings is therefore important-a stable, comfortable, and safe environment should be fostered; soft light, quiet, and familiar faces are reassuring.
The key to treatment lies in calming the acute state while addressing the cause, if apparent and appropriate. A notable example is the mental clouding, hallucinations, confusion, and restlessness associated with opioid toxicity, which can be eased with haloperidol while the opioid dose is reviewed. In general, choice of drug treatment depends on the likely cause. Doses are titrated up or down to achieve the desired effect, and the situation should be reviewed regularly and often until the acute 
Opioid treatment for pain control
If a patient is experiencing distressing twitching or jerks then metabolic disorders, opioid toxicity, or drugs that lower seizure threshold should be considered. A review of medication and treatment with a benzodiazepine or anticonvulsant (such as clonazepam orally, diazepam rectally, or midazolam subcutaneously) is indicated. Anxiety or distress not responding to general supportive measures may be helped by diazepam or midazolam, but it should always be remembered that a patient may be suffering from an emotional or spiritual anguish that cannot be relieved by drugs.
Nausea and vomiting
If antiemetics have been needed within the previous 24 hours then continuation is advisable. Nausea and vomiting may rarely occur as a new symptom at this time ( < 10% of cases), and treatment of the likely cause is preferred if this is practical in the clinical situation, otherwise an appropriate antiemetic should be selected. If the aetiology is unclear then choose a centrally acting or broad spectrum antiemetic in the first instance.
Occasionally, more than one antiemetic is required if resistant vomiting of a multifactorial cause exists. Subcutaneous administration of antiemetics is preferable, but suppositories (such as prochlorperazine, cyclizine, or domperidone) may be useful if no syringe driver is available. Antiemetic treatment that has been initiated for bowel obstruction should be continued.
Emergency situations
Appropriate and timely action has an important immediate effect on patients and families. It can also influence bereavement and future coping mechanisms of both lay and professional carers. Emergencies can sometimes be anticipated: thus, previous haemoptysis may predict haemorrhage, bone metastases predict pathological fracture, enlarging upper airway tumour predict stridor, and previous hypercalcaemia predict confusion.
Some emergencies may be preventable. For example, a patient with a brain tumour who can no longer take corticosteroids may have a seizure unless anticonvulsant treatment is maintained: subcutaneous infusion of midazolam (starting at 30 mg/24 hours) and rectally administered diazepam (10 mg) may be the strategy required.
However, most emergencies in the last 48 hours are irreversible, and treatment should be aimed at the urgent relief of distress and concomitant symptoms. Drugs should be made available for immediate administration by nursing staff without further consultation with a doctor. Directions regarding use should be written clearly in unambiguous language. Useful drugs are injections of midazolam (5-10 mg if patient not previously exposed to benzodiazepine, otherwise titrate as appropriate) and diamorphine (5-10 mg if no prior exposure to opioid, otherwise a sixth to a third of the 24 hour dose).
Haemorrhage is distressing and memorable for both patients and carers. Haemoptysis, haematemesis, and erosion of a major artery such as the carotid are visually traumatic. The prompt use of drugs, dark coloured towels to make the view less distressing (green surgical towels in hospital), and warmth will aid comfort. In these situations death may occur quickly. A supportive presence is helpful, and explanations to patients and their carers of what is being done will help minimise distress in a crisis. 
Management of restlessness and confusion
Support
Support means recognising and addressing the physical and emotional issues that may face patients, families, and carers during this time. Honesty, listening, availability, and assurance that symptom control will continue are valued by patients and carers. Fears or religious concerns should be acknowledged and addressed appropriately, and respect for cultural differences should be assured. Explain what is happening, what is likely to happen, the drugs being used, the support available, and how the family can help with care. Lack of practical support is one of the commonest reasons for admission to hospital or hospice at this time, and, therefore, consideration should be given to extra help-such as Marie Curie nurses (organised through the district nursing service) to give carers rest and support. An assessment of the risk of bereavement allows care to be planned for the family after the patient's death. Professional carers may also need support, particularly if the last 48 hours have been difficult, and this requires an open line of communication. I will limit my response to the management of acute pain. As a consequence of an intercollegiate report (and other guidelines) most acute surgical hospitals now offer an acute pain service led by a consultant anaesthetist. 1 2 The first action might be to contact the local pain service, which should be able to advise on the special needs of the patient.
Risk factors for bereavement
The symptoms described are common and multifactorial, so the next step should be to establish that they are related to opioid treatment. One approach might be to institute a placebo controlled opioid challenge in hospital. But a patient's response to opioids is very different in the pain free setting and a challenge is not necessarily a reliable predicator. If the patient is sensitive to opioids the solution may simply be to find the opioid which best suits him or her, although the evidence that equianalgesic doses of different opioids vary in their side effect profile is not great.
3 Pethidine, by virtue of its metabolite norpethidine, is particularly prone to inducing serious toxicity to the central nervous system, especially in patients with renal failure, and thus has no role in pain management.
2 3 Some high potency opioids-for example, fentanyl-do have a reputation for producing less cardiovascular side effects than "older" opioids. Their use has hitherto been restricted to surgical anaesthesia, but they are now finding a place outside the operating theatre.
Sophisticated techniques of opioid administration, while not appropriate in all patients, may help the patient. A particular advance has been patient controlled analgesia.
1 2 This involves parenteral drug delivery via a device, which allows the patient to self administer small preset boluses from a reservoir. One advantage of this biological feedback system is that the delivered dose is titrated to the individual requirement of the patient. Consequently, the plasma concentration of opioid is more likely to remain within the therapeutic range, when compared with intermittent nurse administered injections. The recent advent of parenteral preparations of potent non-steroidal anti-inflammatory drugs means that these drugs are now finding a place in acute pain management. While their relatively low analgesic efficacy limits their use as a sole analgesic after major surgery, they may usefully be combined with patient controlled analgesia. The safety of perioperatively administered non-steroidal anti-inflammatory drugs has yet to be fully established.
Finally, regional anaesthesia offers an underused alternative to systemic opioid analgesia, particularly for wounds of the trunk or limbs.
1 2 Catheters may be placed in the epidural space or brachial plexus sheath to allow continuous infusion of local anaesthetic over several days. A useful approach is epidural delivery of a combination of local anaesthetic and opioid, the advantage being that the opioid can be delivered at a high concentration directly to its spinal site of analgesia. This combination approach limits not only the systemic side effects of opioids, but also the motor block associated with local anaesthetics.
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